News | Radiation Therapy | August 09, 2016

First Data Presented on ViewRay's MRIdian Linac Technology at AAPM 2016

Meeting also highlights system’s biological imaging capabilities

ViewRay, MRIdian image-guided radiotherapy, magnetic resonance imaging, linac, AAPM 2016

August 9, 2016 — ViewRay Inc. announced highlights from the recent 2016 Annual Meeting of the American Association of Physicists in Medicine (AAPM), which featured extensive clinical experience with the company's MRIdian System. This included the first data from the company's MRIdian linear accelerator (Linac) technology, which is currently under development.

For the first time, researchers from the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis and the University of California, Los Angeles (UCLA) gave presentations on the MRIdian Linac technology. The oral presentations, given during the "MR-Linac Design" session at the AAPM meeting, focused on the design and characteristics of the MR-guided Linac technology and summarized data from recent testing performed in ViewRay's Mountain View, Calif. facility. Speakers highlighted ViewRay's patented magnetic and radio frequency shielding technology that ensures minimal interaction between the linear accelerator and the magnetic resonance imaging (MRI) magnetic field, addressing the fundamental incompatibility of the two technologies that has previously made it impossible to combine them. Quantitative data were presented demonstrating the ability of this compact system to image and deliver radiation simultaneously.

ViewRay's MRIdian System was also featured in oral presentations in the "Imaging Assessment of Treatment Response" session at the AAPM meeting. Researchers from UCLA have successfully developed a diffusion MRI technique on the MRIdian System, which quantifies tissue density inside tumors to gauge their response to radiation.

The research presented demonstrates MRIdian's capabilities for on-table anatomical and biological imaging during the course of radiation therapy, reinforcing its role in delivering personalized, adaptive cancer treatment. 

MRIdian users from UCLA; University of Miami; Washington University in St. Louis; and University of Wisconsin, Madison, presented on their first-hand clinical experience treating cancer patients with the system.

The MRIdian Linac technology is presently available for non-clinical research use only. ViewRay expects to complete its U.S. FDA and European CE Mark submissions for MRIdian Linac in the second half of 2016.

For more information: www.viewray.com

Related Content

An illustration based on simulations by Rice University engineers shows a gadolinium ion (blue) in water (red and white), with inner-sphere water -- the water most affected by the gadolinium -- highlighted. The researchers’ models of gadolinium in water show there’s room for improvement in compounds used as contrast agents in clinical magnetic resonance imaging.

An illustration based on simulations by Rice University engineers shows a gadolinium ion (blue) in water (red and white), with inner-sphere water -- the water most affected by the gadolinium -- highlighted. The researchers’ models of gadolinium in water show there’s room for improvement in compounds used as contrast agents in clinical magnetic resonance imaging. Illustration by Arjun Valiya Parambathu

News | Magnetic Resonance Imaging (MRI) | September 20, 2021
September 20, 2021 — ...
Non-oncology doctors’ knowledge of oncology is frequently not up to date, with risks in the communication with patients  

Getty Images

News | Radiation Oncology | September 20, 2021
September 20, 2021 — The rapid pace of developments in the oncology field, mainly brought by cancer immunotherapy, me
Avoiding contrast dyes for imaging tests not necessary if concerned about iodine allergy, peer-reviewed study concludes #MRI

Getty Images

News | Contrast Media Injectors | September 16, 2021
September 16, 2021 — FDB (First Databank), a leading provider of drug and medical device knowledge that helps healthc
Revised guidelines for lung cancer screening eligibility are perpetuating disparities for racial/ethnic minorities, according to a new study in Radiology.

Getty Images

News | Lung Imaging | September 15, 2021
September 15, 2021 — Revised guidelines for...
To get more flexibility and cost savings from storage, healthcare organizations are increasing their investments in the cloud
Feature | Information Technology | September 15, 2021 | By Kumar Goswami
Healthcare organizations today are storing petabytes of medical imaging data — lab slides,...
Figure 1: MWT Schematic of a typical setup for detecting malignant tissues/tumors.

Figure 1: MWT Schematic of a typical setup for detecting malignant tissues/tumors.

Feature | Radiology Imaging | September 14, 2021 | By Brendon McHugh
As with all imaging technologies, COVID-19 is expected to continue to negatively impact the market.

Courtesy of Grand View Research

Feature | Magnetic Resonance Imaging (MRI) | September 14, 2021 | By Melinda Taschetta-Millane
With a wealth of landmark studies in Breast, Cervical, Melanoma, Prostate, Colorectal, Oesophagus, Endocrine and Lung cancer, the ESMO Congress 2021 is a clear demonstration that oncology research has once again gathered momentum after being temporarily stopped in its tracks by the outbreak of the virus

Getty Images

News | Radiation Oncology | September 13, 2021
September 13, 2021 — At the opening press conference of the ...